RxDoctor Payments Data

Nishant Sethi, MD

Interventional Cardiology · Scranton, PANPI 1306070735

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $835,656 of the $1,335,809 with a category attached, or 62.6%. Medtronic accounts for 75.3% of it on its own, with 31 other manufacturers making up the rest. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,335,809in general payments, 2019–2025

Across 1,667 payments — averaging $801.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1M
  • Abbott$232K
  • Edwards Lifesciences$76K
  • Bard Peripheral Vascular, Inc.$14K
  • Boston Scientific$4K
  • Abiomed$1K
  • plus $4K from 26 others

What the payments were for

  • Consulting fees$168,93813%
  • Speaking & faculty fees$835,65663%
  • Travel & lodging$286,69921%
  • Food & beverage$44,3613%
  • Education$870%
  • Other$680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,335,809 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$282,373
Medicare patients
537
Services billed
2,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$144,487
EntrestoSacubitril/Valsartan92$93,510
XareltoRivaroxaban16$14,955
BrilintaTicagrelor13$10,604
Metoprolol Succinate234$3,590
ClopidogrelClopidogrel Bisulfate375$3,057
Atorvastatin Calcium226$2,493
Isosorbide Mononitrate ErIsosorbide Mononitrate94$1,732
Warfarin Sodium89$1,517
Rosuvastatin Calcium79$1,412
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$1,408
Carvedilol82$1,156
Amlodipine Besylate105$803
Ezetimibe40$745
Pantoprazole Sodium41$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$271$144,487172 claims
NovartisEntresto$712$93,51092 claims
Johnson & JohnsonXarelto$61$14,95516 claims
AstraZenecaBrilinta$54$10,60413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →